Baseline Productions

Baseline Productions Net Tangible Assets

The Net Tangible Assets of Baseline Productions (BSSP) as of Nov 15, 2026 is -1.58 M USD. In the previous year, Net Tangible Assets was -1.52 M USD — a change of 4.47% (lower).

Net Tangible Assets

-1.58 MUSD

YoY

4.47%

Last updated:

Net Tangible Assets of Baseline Productions is 2020 -1.58 M USD. Net Tangible Assets of Baseline Productions was 2019 -1.52 M USD. It decreases by 4.47% lower compared to the previous year.

The Baseline Productions Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2014
-407,605.00 USD
Jan 1, 2019
-1.52 M USD
Jan 1, 2020
-1.58 M USD
The Baseline Productions Net Tangible Assets history
YEARNet Tangible AssetsYoY
-1.58 MUSD+4.47%
-1.52 MUSD+271.90%
-407,605.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baseline Productions Stock analysis

What does Baseline Productions do? Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions. Baseline Productions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baseline Productions stock

Net Tangible Assets of Baseline Productions is -1.58 M USD in 2020.

Net Tangible Assets of Baseline Productions changed from -1.52 M USD to -1.58 M USD, representing a 4.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Baseline Productions since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Baseline Productions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Baseline Productions

All Key Metrics — Baseline Productions